CIC Inserm 1406 - Grenoble

Qui sommes nous ?

Le centre d’investigation clinique de Grenoble (Inserm CIC1406, coordonné par le Pr Alexandre Moreau-Gaudry) comporte deux modules, le module plurithématique (coordonné par le Pr Matthieu Roustit) et le module Innovations Technologiques (coordonné par le Pr Alexandre Moreau-Gaudry). Le module plurithématique développe une partie de sa recherche sur les méthodologies innovantes en recherche clinique et pharmacoépidémiologie, portée par le Pr Matthieu Roustit et le Dr Charles Khouri.

Les travaux et apports méthodologiques du CIC concernent notamment :

• Les essais randomisés individuels (n-of-1) (Roustit, Ann Intern Med 2018; Giai, Stat in Med 2023)
• Les essais à contrôles externes (Cucherat, Therapie 2020 ; Larrouquere, CPT 2020)
• L'analyse de signaux de disproportionalité (Renoud, JAMA Intern Med 2021 ; Khouri, JCE 2021a ; Mouffak, JCE 2021 ; Khouri, JCE 2021b)
• Les essais plateformes (Roustit, Therapie 2022)
• La réponse placebo (Roustit, Semin Arthritis Rheum 2022)

Nos publications majeures

• Giai J, Péron J, Roustit M, Cracowski JL, Roy P, Ozenne B, Buyse M, Maucort-Boulch D. Individualized Net Benefit estimation and meta-analysis using generalized pairwise comparisons in N-of-1 trials. Stat Med. 2023 Jan 3. doi: 10.1002/sim.9648.
• Roustit M, Demarcq O, Laporte S, Barthélémy P, Chassany O, Cucherat M, Demotes J, Diebolt V, Espérou H, Fouret C, Galaup A, Gambotti L, Gourio C, Guérin A, Labruyère C, Paoletti X, Porcher R, Simon T, Varoqueaux N. Platform trials. Therapie. 2022 Dec 5:S0040-5957(22)00277-3
• Roustit M, Jullien A, Jambon-Barbara C, Goudon H, Blaise S, Cracowski JL, Khouri C. Placebo response in Raynaud's Phenomenon clinical trials: The prominent role of regression towards the mean. Semin Arthritis Rheum. 2022 Dec;57:152087.
• Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, Cracowski JL. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database.  JAMA Intern Med. 2021 Sep 1;181(9):1243-1245.
• Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, Cracowski JL. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021 Jun;134:14-21.
• Mouffak A, Lepelley M, Revol B, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL, Khouri C. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. J Clin Epidemiol. 2021 Oct;138:73-79
• Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL.A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J Clin Epidemiol. 2021 Nov;139:191-198.
• Roustit M, Giai J, Gaget O, Khouri C, Mouhib M, Lotito A, Blaise S, Seinturier C, Subtil F, Paris A, Cracowski C, Imbert B, Carpentier P, Vohra S, Cracowski JL. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. Ann Intern Med. 2018 Nov 20;169(10):694-703.
• Larrouquere L, Giai J, Cracowski JL, Bailly S, Roustit M. Externally Controlled Trials: Are We There Yet? Clin Pharmacol Ther. 2020 Nov;108(5):918-919.
• Cucherat M, Laporte S, Delaitre O, Behier JM; participants of Giens XXXV Round Table Clinical Research; d'Andon A, Binlich F, Bureau S, Cornu C, Fouret C, Hoog Labouret N, Laviolle B, Miadi-Fargier H, Paoletti X, Roustit M, Simon T, Varoqueaux N, Vicaut E, Westerloppe J. From single-arm studies to externally controlled studies. Methodological considerations and guidelines. Therapie. 2020 Jan-Feb;75(1):21-27.

Contactez-nous

CIC 1406 Grenoble

Centre Hospitalier Universitaire de Grenoble - Rond point de la Croix de Vie - Pavillon Taillefer

CS 10214 38043 GRENOBLE CEDEX 9

cic@chu-grenoble.fr